The Journal of Precision Medicine

Almac Diagnostic Services’ claraT Report Assists Researchers In Uncovering New Oncology Findings

2022-01-13T23:00:44-05:00January 13th, 2022|

Almac Diagnostic Services, a member of the Almac Group, is delighted to announce that its unique software driven solution for gene expression data analysis - claraT - has assisted oncology researchers at The University of Arkansas for Medical Sciences (US) and Queen’s University Belfast (UK) in the study of brain and breast cancers. The [...]

GenomOncology Pathology Workbench to Support OmniSeq INSIGHT℠, a Genomic and Immune Profiling Test That Identifies Potential Treatment and Clinical Trial Options for Solid Tumors

2022-01-13T22:56:43-05:00January 13th, 2022|

GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors. OmniSeq INSIGHT combines genomic and immune profiling to comprehensively characterize a patient's tumor to identify potential treatment and clinical trial options. [...]

SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

2022-01-13T22:48:55-05:00January 13th, 2022|

SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT04994795). Since officially launching last month, 12 sites across 5 countries have already signed up for participation in the study. Despite [...]

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

2022-01-13T22:42:50-05:00January 13th, 2022|

Illumina Inc. (NASDAQ: ILMN) announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer. We are delighted that Boehringer Ingelheim has chosen Illumina to be its long-term [...]

Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference

2022-01-13T22:32:12-05:00January 13th, 2022|

Bristol Myers Squibb highlighted progress against the Company’s growth strategy and outlook for 2022 during a presentation on January 10th, 2022 at the 40th Annual J.P. Morgan Healthcare Conference.“We are successfully transforming the company by further diversifying our product portfolio, launching breakthrough new medicines that benefit our patients and advancing a robust product pipeline that [...]

Coriell Life Sciences Achieves HITRUST CSF® Certification for GeneDose Live Clinical Decision Support System

2022-01-10T12:03:10-05:00January 10th, 2022|

With a steadfast commitment to protecting personal healthcare information, Coriell Life Sciences (CLS) – a leader in precision medicine dedicated to personalized medication safety – is proud to announce its GeneDose Live™ clinical decision support system (CDSS) has earned Certified status for information security by HITRUST. This achievement places CLS in an elite group [...]

Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins

2022-01-06T12:19:28-05:00January 6th, 2022|

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion. Based in Cranbury, New Jersey, PeproTech is a [...]

Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function

2022-01-06T11:44:06-05:00January 6th, 2022|

Novartis today announced a collaboration with Alnylam to leverage Alnylam’s proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure. “There [...]

RareCyte® Inc. reports significant 2021 growth of Precision Biology™ Services business and customer uptake of Orion™ Spatial Biology instruments and reagents

2022-01-06T11:40:22-05:00January 6th, 2022|

RareCyte Inc., (“RareCyte” or “The Company”) a leading provider of Precision Biology products and services recognized over 100% sales growth in their Services business in 2021. They also saw significant uptake by early adopters of their Orion instruments and consumables by global key opinion leaders in support of fast, subcellular whole slide spatial analysis. [...]

DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche

2022-01-06T11:33:57-05:00January 6th, 2022|

DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, announced the completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014. Accounts and funds advised by T. Rowe Price Associates and [...]

Go to Top